Matrixyl Research: What 29 Studies Show (2026) | RetatrutideCompare

Matrixyl — 29 studies indexed on PubMed. Stimulates fibroblast collagen I, III and fibronectin synthesis in vitro and in vivo on photoaged skin. Half-life: Topical, local. FDA status: Cosmetic ingredient.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Matrixyl?

There are approximately 29 studies indexed on PubMed that mention Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS), based on a search last updated 2026-06-18.

Is Matrixyl FDA-approved?

FDA status: Cosmetic ingredient.

How does Matrixyl work?

Stimulates fibroblast collagen I, III and fibronectin synthesis in vitro and in vivo on photoaged skin.

Stimulates fibroblast collagen I, III and fibronectin synthesis in vitro and in vivo on photoaged skin.

Reference facts

Also known as
Palmitoyl Pentapeptide-4, Pal-KTTKS
Category
Cosmetic & Skin
Mechanism of action
Stimulates fibroblast collagen I, III and fibronectin synthesis in vitro and in vivo on photoaged skin.
Targets
Fibroblast ECM gene expression
Indications under research or approved
Cosmetic anti-aging
Regulatory status (reference entry)
Cosmetic ingredient
Half-life
Topical, local
Sequence
KTTKS
Sequence notes
Pentapeptide N-acylated with palmitic acid for skin penetration; KTTKS is the cell-binding fragment of type I collagen.
Molecular weight (Da)
802
Originator / sponsor
Sederma
First reported
1993

Primary References

Explore research articles about Matrixyl

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.